echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Lancet Haematol: Venetoclax combined with intensive chemotherapy in the treatment of AML or high-risk MDS

    Lancet Haematol: Venetoclax combined with intensive chemotherapy in the treatment of AML or high-risk MDS

    • Last Update: 2021-08-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Adding Venetoclax, a BCL2 inhibitor, to low-intensity therapy has been shown to increase the overall survival rate of elderly (75 years or older) patients with newly diagnosed acute myeloid leukemia
    .


    The purpose of this study is to clarify the activity of Venetoclax combined with intensive chemotherapy in acute myeloid leukemia patients 65 years of age and younger


    The cohort study was completed at the MD Anderson Cancer Center in the United States and is part of the single-center, single-arm Phase II CLIA trial
    .


    This article reports an independent cohort study on the safety and activity of adding Venetoclax to intensive chemotherapy


    The test patients were newly diagnosed patients with previously untreated acute myeloid leukemia, mixed phenotypic acute leukemia, or high-risk myelodysplastic syndrome, aged 18-65 years old, and were given clarithromycin (5 mg/m 2 ) and albine sugar cytidine (<60 years in patients with 1.
    5 g / m2, ≥60 years G patient.
    1 / m 2 ) infusion on days 1-5, daunorubicin (10 mg / m2) for 1-3 days infusion
    .


    Consolidation therapy: clarithromycin (5 mg/m2) and cytarabine (1 g/m 2 in patients <60 years old , 0.


    2 2 2 2

    From February 25, 2019 to March 23, 2021, 77 patients were reviewed for eligibility, and 50 of them were included in the study
    .


    The median age of the tested patients was 48 years old


    Forty-seven (94%) patients achieved composite complete remission, and the same proportion of patients also achieved overall remission.


    Various endpoints

    Various endpoints

    Of the 45 patients, 37 (82%) had undetectable residual disease (MRD )
    .


    At a median follow-up of 13.


    37 out of 45 patients (82%) had no residual disease detected (MRD 37 out of 45 patients (82%) had no residual disease detectable (at the 12th month of


    Infect

    In summary, for newly diagnosed patients with acute myeloid leukemia or high-risk myelodysplastic syndromes, adding Venetoclax to the intensive chemotherapy regimen is safe and effective, and can produce a high rate of durable MRD negative remission and improve event-free Survival rate and overall survival rate
    .

    For newly diagnosed patients with acute myeloid leukemia or high-risk myelodysplastic syndromes, adding Venetoclax to intensive chemotherapy is safe and effective, can produce a high rate of durable MRD negative remission, and improve event-free survival and overall survival Rate
    .


    For newly diagnosed patients with acute myeloid leukemia or high-risk myelodysplastic syndromes, adding Venetoclax to intensive chemotherapy is safe and effective, can produce a high rate of durable MRD negative remission, and improve event-free survival and overall survival Rate


    Original source:

    Tapan M Kadia, et al.


    Venetoclax plus intensive chemotherapy with cladribine, idarubicin , and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.